Al-Hussainy Nour, Kragholm Kristian, Lundbye-Christensen Søren, Torp-Pedersen Christian, Pareek Manan, Krohn Therkelsen Susette, Lip Gregory Y H, Riahi Sam
Cardiology, Aalborg University Hospital, Aalborg, Denmark
Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Heart. 2026 Feb 12;112(5):253-260. doi: 10.1136/heartjnl-2024-325343.
Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation (AF) presents a clinical dilemma, with limited evidence on the balance between stroke prevention and recurrent bleeding risk.
Using nationwide Danish registries (2012-2021), we identified AF patients (Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65-74, and Sex category (female) (CHA₂DS₂-VASc score ≥2)) who experienced a first serious bleeding event while on DOAC therapy. Patients were grouped by timing of DOAC restart: within 60 days ('early restarters') vs after 60 days ('late restarters'). HRs for stroke, recurrent bleeding and a composite endpoint (stroke or serious bleeding) were estimated using multivariable Cox models. A secondary analysis examined outcomes across six time-varying antithrombotic treatment regimens.
Among 10 291 patients who survived 60 days postbleeding, 5970 restarted DOAC early and 4321 later. The early restart group had a lower rate of stroke (HR 0.89; 95% CI 0.74 to 1.08), but the interval includes both moderate benefit and no clear difference, indicating uncertainty in the stroke reduction. Recurrent bleeding was more frequent in early restarters (HR 1.21; 95% CI 1.07 to 1.36). In the time-varying analysis, DOAC monotherapy was associated with reduced stroke risk compared with no treatment (HR 0.78; 95% CI 0.68 to 0.89). However, bleeding risk was also higher during DOAC monotherapy (HR 1.26; 95% CI 1.15 to 1.38).
Restarting DOACs early after a serious bleeding event in AF patients may reduce stroke risk but is associated with an increased risk of recurrent bleeding. DOAC monotherapy appears to offer the best stroke protection, though with elevated bleeding risk. These findings highlight the need for individualised decision-making and further trials to define optimal timing for DOAC resumption.
心房颤动(AF)患者发生严重出血事件后重新开始使用直接口服抗凝剂(DOACs)存在临床困境,关于预防中风和复发出血风险之间平衡的证据有限。
利用丹麦全国性登记系统(2012 - 2021年),我们确定了在接受DOAC治疗期间发生首次严重出血事件的AF患者(充血性心力衰竭、高血压、年龄≥75岁(加倍)、糖尿病、中风(加倍)、血管疾病、年龄65 - 74岁以及性别类别(女性)(CHA₂DS₂ - VASc评分≥2))。患者按DOAC重新开始使用的时间分组:60天内(“早期重新使用者”)与60天后(“晚期重新使用者”)。使用多变量Cox模型估计中风、复发出血和复合终点(中风或严重出血)的风险比(HRs)。一项二次分析检查了六种随时间变化的抗栓治疗方案的结局。
在出血后存活60天的10291例患者中,5970例早期重新开始使用DOAC,另外4321例较晚重新开始使用。早期重新开始使用组的中风发生率较低(HR 0.89;95%CI 0.74至1.08),但该区间既包括适度获益也包括无明显差异,表明在降低中风方面存在不确定性。早期重新使用者复发出血更频繁(HR 1.21;95%CI 1.07至1.36)。在随时间变化的分析中,与不进行治疗相比,DOAC单药治疗与降低中风风险相关(HR 0.78;95%CI 0.68至0.89)。然而,DOAC单药治疗期间出血风险也更高(HR 1.26;95%CI 1.15至1.38)。
AF患者发生严重出血事件后早期重新开始使用DOACs可能会降低中风风险,但与复发出血风险增加相关。DOAC单药治疗似乎提供了最佳的中风保护,尽管出血风险升高。这些发现凸显了个体化决策的必要性以及进一步试验以确定DOAC恢复使用的最佳时机。